The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Aclaris Therapeutics Inc’s current trading price is -71.78% away from its 52-week high, while its distance from the 52-week low is 172.79%. The stock’s price range for this period has been between $0.59 and $5.70 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 1.16 million for the day, a number notably higher than the average daily volume of 0.44 million over the last three months.
In terms of market performance, Aclaris Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $5.70 on 11/06/23, and the lowest value was recorded at $0.59 on 11/13/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Aclaris Therapeutics Inc (ACRS) has experienced a quarterly rise of 22.90% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 114.86M and boasts a workforce of 91 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2146, with a change in price of +0.5600. Similarly, Aclaris Therapeutics Inc recorded 683,167 in trading volume during the last 100 days, posting a change of +53.33%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ACRS stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.02.
ACRS Stock Stochastic Average
Aclaris Therapeutics Inc’s raw stochastic average for the past 50 days is presently 83.05%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 83.05%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 92.27% and 91.27%, respectively.
ACRS Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The index has shown a price gain of 53.33% this year. Over the last six months, there has been a weaker performance of 31.97%. The price of ACRS fallen by 37.61% during the last 30 days period. For the last 5-days stocks have improved 33.06%.
